What is EasyCheck360®?
›
EasyCheck360® is a blood-based screening test that evaluates circulating tumor cells (CTCs) and CTC clusters to assess risk of presence of 30 carcinoma types.
Is this a diagnostic test for cancer?
›
No. EasyCheck360® is a screening and risk assessment test and is not intended to be used as a standalone diagnostic tool.
What does a “CTC suspected” result mean?
›
It indicates that circulating tumor celllike signals were observed in the sample, suggesting a moderate risk of presence of carcinoma and requiring clinical follow-up.
Can the test identify the exact cancer type or organ?
›
In some cases, limited marker expression may suggest a probable organ of origin, but it may not be conclusive.
What should be done after a positive or suspected result?
›
Further evaluation by a physician is recommended, which may include imaging and other diagnostic investigations as clinically indicated.
Does a negative result mean I am completely cancer-free?
›
A negative result indicates that no detectable CTC-related signals were observed at the time of testing, but it does not completely rule out the possibility of early-stage or undetectable disease.
How often should the test be taken?
›
Frequency depends on individual risk factors and physician recommendation. In general preventive screening scenarios, it may be considered annually or as advised by a healthcare professional.
Who can take this test?
›
It is intended for asymptomatic adults aged 30 years and above with no prior history of cancer as part of preventive screening.
Can the test have false results?
›
Yes. The test acknowledges the possibility of both false positives and false negatives due to biological variability and technical limitations.
How is the sample collected?
›
A standard peripheral blood sample is collected by a trained technician.
How can I learn more about the test?
›
What is Trublood®?
›
Trublood® is a non-invasive, blood-based cancer detection and triaging test designed to identify malignancy in suspected cases of solid organ and brain cancers.
How does Trublood® work?
›
The test isolates and analyzes circulating tumor cells (CTCs) from a patient’s blood sample using advanced cellular analysis techniques.
What does Trublood® detect?
›
It detects live circulating tumor cells and tumor-associated cellular signals that may indicate the presence of malignancy.
Is Trublood® a replacement for tissue biopsy?
›
No. Trublood® serves as a triaging and supportive diagnostic tool to help guide decisions regarding invasive biopsy procedures.
Who should undergo Trublood® testing?
›
The test is suitable for individuals with suspected cancer, inconclusive biopsy findings, or patients seeking a non-invasive diagnostic option.
What cancers can Trublood® help evaluate?
›
It is applicable for most solid organ tumors and brain cancers.
What are the advantages of Trublood® compared to tissue biopsy?
›
It is non-invasive, safer, less painful, repeatable, and does not require hospitalization or anesthesia.
Can Trublood® be repeated multiple times?
›
Yes. Since it is blood-based, testing can be performed sequentially whenever clinically required.
How accurate is Trublood®?
›
The test has demonstrated an overall sensitivity of 99.8% and specificity of 95.4% in clinical validation studies.
How can I learn more about Trublood®?
›
What makes Exacta™ different from standard genomic testing?
›
Exacta™ goes beyond mutation detection by integrating genomic, transcriptomic, and functional analysis. It not only identifies alterations but also evaluates tumour behaviour and actual drug response to guide treatment selection.
When should Exacta™ be considered in the treatment journey?
›
Exacta™ is particularly valuable in complex scenarios such as treatment failure, relapse, aggressive disease, or when standard options are limited or unclear.
Can Exacta™ help after multiple lines of therapy have failed?
›
Yes. Exacta™ is specifically designed to uncover hidden resistance mechanisms and identify alternative treatment strategies, even in heavily pre-treated or refractory cancers.
Does Exacta™ support chemotherapy decision-making?
›
Yes. Unlike conventional tests, Exacta™ includes functional chemosensitivity testing on live tumour cells to help identify which chemotherapy drugs are more likely to be effective.
Is Exacta™ only useful for advanced-stage cancers?
›
No. While highly valuable in advanced settings, Exacta™ can also support treatment planning in newly diagnosed aggressive or hard-to-treat cancers.
What types of samples are required for Exacta™?
›
Exacta™ can be performed using tumour tissue, blood samples, or a combination of both, depending on the clinical scenario and sample availability.
How does Exacta™ help in selecting targeted therapies?
›
By analysing both genetic alterations and pathway activity, Exacta™ identifies therapies that are most likely to be effective based on how the tumour is functioning—not just which mutations are present.
Does Exacta™ provide information on immunotherapy response?
›
Yes. Exacta™ evaluates relevant biomarkers such as TMB, MSI, and other immune-related indicators to support immunotherapy decision-making.
Can Exacta™ identify clinical trial options?
›
Yes. The report includes relevant clinical trial opportunities aligned with the patient’s molecular and functional tumour profile.
How are Exacta™ results presented?
›
Results are delivered as a clear, structured report with prioritised treatment options, supporting evidence, and insights to help guide personalised clinical decisions.
How can I get Exacta™ testing done?
›
What is Pinaka™ and how is it different from tissue biopsy testing?
›
Pinaka™ is a blood-based test that evaluates cancer biomarkers on circulating tumor cells (CTCs). Unlike tissue biopsy, it does not require invasive procedures and can provide biomarker status from tumor cells currently present in circulation.
What biomarkers are assessed in the Pinaka™ test?
›
Pinaka™ evaluates clinically relevant biomarkers including PD-L1, Estrogen Receptor (ER), Progesterone Receptor (PR), and HER2 using immunocytochemistry (ICC).
What type of results does the test provide?
›
The test reports:
- Presence or absence of circulating tumor cells (CTCs)
- Biomarker status as positive or negative
- Standardized interpretation based on defined thresholds
Does Pinaka™ provide treatment recommendations?
›
No. Pinaka™ provides biomarker status information. Clinical decisions should be made by the treating physician based on guidelines, clinical context, and additional diagnostic inputs.
When is Pinaka™ most useful in clinical practice?
›
It is particularly useful when:
- Tumor tissue is unavailable or insufficient
- Repeat biopsy is not feasible
- Real-time biomarker status is required
- Disease biology may have evolved over time
How is the sample collected for the test?
›
A simple peripheral blood sample is collected in a routine clinical setting, making the process minimally invasive and convenient.
How does Pinaka™ reflect current tumor biology?
›
By analyzing circulating tumor cells shed from active disease sites, the test provides a snapshot of current biomarker expression rather than relying on historical tissue samples.
How reliable is biomarker assessment on CTCs?
›
Biomarker expression on CTCs has shown correlation with tumor tissue in multiple clinical settings, though results should always be interpreted in conjunction with overall clinical findings.
Can Pinaka™ replace tissue biopsy?
›
Pinaka™ is not a complete replacement for tissue biopsy. It serves as a complementary or alternative option in scenarios where tissue sampling is limited, not feasible, or requires re-evaluation.
Who should consider using Pinaka™?
›
Pinaka™ may be considered by oncologists for patients where non-invasive biomarker assessment is needed to support clinical evaluation, especially in advanced or evolving disease contexts.
How can I get Pinaka™ testing done?
›
What is Comprehensive Genomic Profiling (CGP)?
›
No two cancers are exactly alike. Comprehensive Genomic Profiling (CGP) is a laboratory test that analyzes a tumour’s genetic code to identify specific “driver” mutations responsible for cancer growth.
Why is CGP important in cancer treatment?
›
Traditional treatments like chemotherapy are often one-size-fits-all. CGP helps clinicians identify targeted therapies-treatments designed to specifically act on cancer-driving mutations—often enabling more precise and effective care with fewer side effects.
What can be expected from CellDx-Tissue testing?
›
- No extra procedures: Uses tissue already collected during biopsy or surgery, avoiding additional invasive steps
- Fast answers: Results are typically available within approximately one week, enabling timely clinical decisions
- A clear path forward: Comprehensive, structured tumour mutation profiling to support the oncologist's next conversation
How is CellDx-Tissue ordered?
›
CellDx-Tissue can be ordered by oncologists or healthcare providers through the designated test requisition process or by contacting our support team.
What tumour types is CellDx-Tissue suitable for?
›
CellDx-Tissue evaluates hundreds of genes in a single assay, enabling a broader and more clinically meaningful understanding of tumour biology and is suitable for molecular evaluation of solid tumours.
How is CellDx-Tissue different from single-gene or hotspot testing?
›
CellDx-Tissue evaluates hundreds of genes in a single assay, enabling a broader and more clinically meaningful understanding of tumour biology compared to limited single-gene tests.
What is the turnaround time (TAT) for CellDx-Tissue?
›
Results are typically available within 5 business days from sample receipt.
Is CellDx-Tissue performed in an accredited laboratory?
›
CellDx-Tissue testing is conducted in a CAP-accredited and CLIA-certified laboratory, ensuring high standards of quality and reliability.
How are results reported?
›
Results are provided in a simplified, clinically intuitive report that includes: Detected genomic variants classified by clinical significance level, ERBB2 amplification status, and ALK/RET/ROS1 fusion status.
How can I access the test results?
›
Results are shared securely with the ordering clinician through designated reporting channels.
Who can I contact for support or queries?
›
Why is multi-omics profiling important in cancer care?
›
Cancer is driven by complex biological processes that may not be fully captured by a single type of analysis. Multi-omics profiling combines different molecular layers to provide a more complete understanding of tumor behavior, enabling more informed treatment selection.
What can be expected from a Proxceq™ report?
›
The report provides a consolidated view of clinically relevant findings, including actionable alterations, biomarker status, pathway insights, and potential therapy options, along with information on relevant clinical trials.
How is Proxceq™ different from conventional genomic tests?
›
Unlike standard tests that focus only on DNA alterations, Proxceq™ integrates genomic, transcriptomic, and biomarker data, offering deeper biological insight and expanded opportunities for targeted and personalized therapies.
What type of sample is required?
›
Proxceq™ is performed on tumor tissue samples, including FFPE blocks or fresh biopsy specimens with adequate tumor content.
Which cancer types is Proxceq™ suitable for?
›
The test can be applied across a wide range of solid tumors where tissue samples are available, particularly in cases where deeper molecular understanding may impact treatment decisions.
What is the turnaround time (TAT)?
›
Results are typically available within 5–7 business days from receipt of the sample, depending on sample quality and completeness of clinical information.
Is Proxceq™ performed in an accredited laboratory?
›
Yes, Proxceq™ is conducted in a certified laboratory environment following established quality standards.
How are results delivered?
›
Results are provided as a structured, easy-to-interpret report designed to support clinical decision-making.
How can I access the test results?
›
Reports are shared securely with the requesting clinician or institution through designated communication channels.
Who can I contact for support or queries?
›
What is Chemo-scale™?
›
Chemo-scale™ is a comprehensive cancer therapy guidance test that evaluates how a patient’s tumor cells respond to different anti-cancer drugs.
How does Chemo-scale™ work?
›
The test studies the effect of chemotherapy and naturopathic drugs on tumor cells isolated from a fresh biopsy sample or Circulating Tumor-Associated Cells (C-TACs) from blood.
What does the test reveal?
›
It identifies sensitivity and low responsive drug profiles of tumor cells to multiple chemotherapeutic agents.
Is Chemo-scale™ personalized for each patient?
›
Yes. The analysis is specific to the individual patient’s tumor biology.
Can the test be performed without a tissue biopsy?
›
Yes. The test can utilize Circulating Tumor-Associated Cells (C-TACs) isolated from peripheral blood.
Who should undergo Chemo-scale™ testing?
›
The test is suitable for patients who have been advised chemotherapy at any stage of their disease.
What are the advantages of Chemo-scale™?
›
It helps identify the drugs of choice, reduces trial-and-error treatment selection, and supports more personalized therapy decisions.
Does the test evaluate multiple drugs?
›
Yes. Individual cytotoxic, re-purposed, and naturopathic drugs are analyzed separately to determine their effectiveness against the patient’s tumor cells.
How can Chemo-scale™ improve treatment planning?
›
By providing tumor-specific drug response information, it helps clinicians choose therapies with greater precision.
Is the testing process non-invasive?
›
The test can be performed non-invasively using blood-based C-TAC analysis when appropriate.
How can I learn more about Chemo-scale™?
›
What does Cancertrack™ detect?
›
It detects circulating tumor cells (CTCs) and tumor-derived DNA and RNA in the bloodstream to assess cancer activity in real time.
How is Cancertrack™ different from imaging scans?
›
It identifies molecular changes in the blood that may appear earlier than changes visible on imaging, enabling more proactive treatment decisions.
Can Cancertrack™ replace a biopsy or imaging?
›
No. It complements existing diagnostic methods by providing continuous molecular monitoring between scans or when tissue is unavailable.
What tumor types is Cancertrack™ suitable for?
›
It is applicable across all solid tumors, as it relies on circulating tumor-derived signals rather than tumor location.
How frequently should Cancertrack™ be performed?
›
Testing can be done at multiple timepoints—baseline, during treatment, and follow-up—based on clinical need.
What kind of insights does the report provide?
›
The report includes cancer activity status, treatment response trends, emerging resistance signals, and actionable molecular changes.
How early can Cancertrack™ detect changes in disease status?
›
It can detect molecular changes weeks to months earlier than conventional methods, depending on tumor biology and burden.
Is Cancertrack™ suitable when tissue is not available?
›
Yes. It is a fully blood-based test and does not require tumor tissue.
Does a negative result rule out cancer?
›
No. Results should be interpreted alongside clinical and imaging findings, as very low disease levels may be below detection limits.
Is the test performed in an accredited laboratory?
›
Yes. Testing is conducted in accredited laboratories with validated processes and expert-reviewed reporting.
How can I get Cancertrack™ testing done?
›
What is ctDNA and why is it important?
›
Circulating tumor DNA (ctDNA) is small fragments of DNA released by cancer cells into the bloodstream. Detecting ctDNA allows for non-invasive monitoring of cancer and early detection of residual disease.
What is minimal residual disease (MRD)?
›
Minimal residual disease refers to a very small number of cancer cells that remain in the body after treatment. These cells are often undetectable through conventional imaging but may lead to cancer recurrence if not identified early.
What makes Target-MRD™ different from other MRD tests?
›
- Combines tumor-informed and tumor-agnostic approaches
- Detects both known and emerging mutations
- Captures tumor heterogeneity and clonal evolution
- Offers a high sensitivity with a limit of detection (LOD) of 0.01%
- CHIP filtering to reduce false positives
Why is combining both approaches important?
›
Using both approaches ensures:
- Detection of known mutations (high specificity)
- Identification of new or evolving mutations (broad coverage)
- Better monitoring of tumor evolution and resistance
When should MRD testing be performed?
›
MRD testing can be performed before treatment initiation to establish a baseline, after completion of treatment, during follow-up monitoring, and at regular intervals (e.g., every 6 months) to track disease status. Your oncologist will determine the optimal timing based on your condition.
Why do I need this test if my scan is clear?
›
Even when scans show no cancer, a few cancer cells may still remain. This test can detect those hidden cells early, helping doctors act before the cancer grows again. Target-MRD™ complements imaging and clinical evaluation. It provides molecular-level insights that imaging alone cannot detect.
How often will I need to repeat the test?
›
This depends on your cancer type and risk. Many patients take it every few months during follow-up, but your doctor will guide you.
How accurate is Target-MRD™?
›
Target-MRD™ offers high sensitivity, with the ability to detect very low levels of disease (down to 0.01% variant allele frequency), making it highly effective for early detection of recurrence.
Is Target-MRD™ suitable for long-term monitoring?
›
Yes. It is specifically designed for longitudinal monitoring, enabling continuous tracking of disease status over time.
What do the results mean?
›
- MRD Positive: Presence of ctDNA suggestive of a higher risk of disease relapse
How can I get Target-MRD™ testing done?
›